Lead switching to resolve undersensing of ventricular tachycardia by a cardiac resynchronization therapy defibrillator
暂无分享,去创建一个
[1] T. Mitsuhashi,et al. JCS/JHRS 2019 Guideline on Non-Pharmacotherapy of Cardiac Arrhythmias. , 2021, Circulation journal : official journal of the Japanese Circulation Society.
[2] T. Noda,et al. Undersensing of ventricular fibrillation by a biventricular implantable cardioverter‐defibrillator: What is the cause and the troubleshooting? , 2019, Journal of arrhythmia.
[3] Jorge G. Quintanilla,et al. Ventricular fibrillation undersensing to calculate a safety threshold for baseline rhythm R-wave amplitudes. , 2018, Journal of electrocardiology.
[4] Michael J Ackerman,et al. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. , 2017, Journal of the American College of Cardiology.
[5] Chad M. House,et al. Management of functional Sprint Fidelis leads at cardiac resynchronization therapy-defibrillator generator replacement: a novel option for preventing inappropriate shocks from lead failure in fragile patients with high risk of sudden death† , 2017, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[6] M. Shoda,et al. 2017 HRS expert consensus statement on cardiovascular implantable electronic device lead management and extraction. , 2017, Heart rhythm.
[7] J. Rojo-álvarez,et al. Safety threshold of R-wave amplitudes in patients with implantable cardioverter defibrillator , 2016, Heart.